JP4955654B2 - 癌の治療のためのp21タンパク質を含んで成るコンジュゲート - Google Patents
癌の治療のためのp21タンパク質を含んで成るコンジュゲート Download PDFInfo
- Publication number
- JP4955654B2 JP4955654B2 JP2008505969A JP2008505969A JP4955654B2 JP 4955654 B2 JP4955654 B2 JP 4955654B2 JP 2008505969 A JP2008505969 A JP 2008505969A JP 2008505969 A JP2008505969 A JP 2008505969A JP 4955654 B2 JP4955654 B2 JP 4955654B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- fusion protein
- antennapedia
- cancer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
- C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Insects & Arthropods (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明は、P21タンパク質が癌の治療に有用であるという知見に基づいている。特に、P21タンパク質が癌治療に使用される少なくとも1つの他の物質と一緒に投与される場合、相乗効果が観察される。
(a)P21タンパク質、あるいはそのホモログ又は機能的フラグメントを含んで成る第一領域;及び
(b)転位因子を含んで成る第二領域、
を含んで成る。
本発明は、治療剤としてP21タンパク質を利用する。P21タンパク質は、治療剤として、単独で又は他の治療剤と組み合わせて使用されうる。他の治療剤と併用される場合、驚くべき相乗効果が観察される。好ましい態様において、P21タンパク質は、当該P21タンパク質を標的細胞へと進入させる転位因子と結合している。
配列番号2:RKKRRQRRR
配列番号3:RKRGRQTYTR YQTLELEKEF HFNRYLTRRR RIEIAHALCL TERQIKIWFQ NRRMKWKKEN
配列番号4:Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys
を有すると言われている。
配列番号5:X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16又は
配列番号6:X16-X15-X14-X13-X12-X11-X10-X9-X8-X7-X6-X5-X4-X3-X2-X1
(ここで、各Xはα−アミノ酸を表しており、X6はトリプトファンを表している;前記ペプチドは、6から10の間に疎水性アミノ酸を含んで成る)
を有すると言われている。
(2)免疫応答修飾剤:抗増殖性免疫抑制剤、コルチコステロイド。
(3)免疫修飾剤:インターフェロン、インターロイキン
(4)モノクローナル;トランスツズマブ、リツキシマブ、アレムツズマブ。
(5)抗菌性薬物:ペニシリン、セファロスポリン、セファマイシン、テトラサイクリン、マクロライド、アミノグリコシド、他の抗菌剤(クロラムフェニコール、フシジン酸、バンコマイシン等)。
(6)ホルモン:甲状腺ホルモン、エストロゲン、プロゲステロン、アンドロゲン、及びそれら全てのアンタゴニスト。
(7)その他:ビタミン、非ステロイド性抗炎症薬(例えば、セレコキシブ、ロフェコキシブ等)、ワクチン、抗血清、抗菌薬、抗ウイルス薬及びステロイド。
細菌性プラスミドクローンは、P21タンパク質単独又はアンテナペディアペプチドとの融合物として構築された。ANTP−P21融合物(「融合タンパク質」)の発現は、誘導後最大3時間であり、この後、グアニジン塩酸塩及び尿素を用いた変性条件下でのタンパク質精製を行った。再生及びリフォールディングの間に、タンパク質沈殿が観察された。このことは、種々の緩衝液が試験される必要があることを示唆した。5種類の緩衝液を試験した;20mMのTris塩基/0.5MのNaCl/0.1% Tween−20(pH8)は、前記タンパク質を溶解状態に維持した。
融合タンパク質の発現をスケールアップして、十分に材料を精製して細胞毒性アッセイを実施した。タンパク質はTrisの代わりにグアニジン塩酸塩溶液中で透析することで、沈殿を防いだ。細胞に取り込まれた場合、細胞内ジスルフィドイソメラーゼ及びシャペロンは機能的タンパク質をもたらすことが予測された。卵巣癌細胞系SKOV−3及び骨肉腫細胞系SAOS−2を、ヒトの体内環境に類似の条件下で、96穴ELISAディッシュ内で生育した(細胞培養設備)。
腫瘍無しのマウスにおける、精製され、放射性標識がされたアンテナペディアタンパク質(単独)の動力学及び生体内分布を試験した。これは、当該タンパク質が血液を介して身体の組織全部に転位するということを示す。結果の要約を図4Aに示す。
SKO−V3腫瘍の実験の後、融合タンパク質であるアンテナペディア−P21は、結腸癌RKO−E6細胞を異種移植したヌードマウスにおいて試験した。これらの細胞は、サイトメガロウイルス(CMV)の制御下で安定的に組み込まれたヒトパピローマウイルス(HPV)E6発癌遺伝子を含む。HPV E6発癌遺伝子は、この系がかなりの機能的p53を欠くまで、正常なp53レベル及び機能の低下をもたらす。
i.リン酸緩衝溶液(一週間に一回、5週間)
ii.2.5mg/mlアンテナペディア−P21融合物(一週間に一回、5週間)
iii.2mgの5−フルオロウラシル/1mgのロイコボリン、0.2mgのオキサリプラチン(一週間に一回、5週間)
iv.2.5mg/mlのアンテナペディア−P21融合物+2mgの5−フルオロウラシル/1mgのロイコボリン、0.2mgのオキサリプラチン(一週間に一回、5週間)
Claims (4)
- (i)a)配列番号1で規定されているアミノ酸配列から成るP21タンパク質、又は配列番号1と少なくとも90%の配列同一性を有し、且つ天然のP21タンパク質の機能を有するそのホモログ、を含んで成る第一領域;及び
b)配列番号3で規定されているアミノ酸配列から成るアンテナペディアホメオドメインを含んで成る第二領域、
を含んで成るコンジュゲート;及び
(ii)化学療法薬、
を含んで成り、前記機能が腫瘍抑制タンパク質として作用し、そしてcyc/CDK4複合体の形成を阻止し、それにより真核生物細胞のG1期停止を生じさせる能力である、組成物。 - 前記コンジュゲートが融合タンパク質の形態である、請求項1に記載の組成物。
- 薬剤として使用するための請求項1又は2に記載の組成物。
- 癌の治療のための医薬の製造のための、請求項1又は2に記載の組成物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0507598A GB0507598D0 (en) | 2005-04-14 | 2005-04-14 | Composition |
GB0507598.1 | 2005-04-14 | ||
PCT/GB2006/001407 WO2006109092A1 (en) | 2005-04-14 | 2006-04-18 | Conjugate comprising p21 protein for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008535512A JP2008535512A (ja) | 2008-09-04 |
JP4955654B2 true JP4955654B2 (ja) | 2012-06-20 |
Family
ID=34611144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008505969A Expired - Fee Related JP4955654B2 (ja) | 2005-04-14 | 2006-04-18 | 癌の治療のためのp21タンパク質を含んで成るコンジュゲート |
Country Status (16)
Country | Link |
---|---|
US (3) | US20080287357A1 (ja) |
EP (1) | EP1869185B1 (ja) |
JP (1) | JP4955654B2 (ja) |
KR (1) | KR20080016798A (ja) |
CN (1) | CN101194017B (ja) |
AT (1) | ATE458819T1 (ja) |
AU (1) | AU2006235742B2 (ja) |
CA (1) | CA2604536A1 (ja) |
DE (1) | DE602006012463D1 (ja) |
DK (1) | DK1869185T3 (ja) |
ES (1) | ES2343972T3 (ja) |
GB (1) | GB0507598D0 (ja) |
PL (1) | PL1869185T3 (ja) |
PT (1) | PT1869185E (ja) |
SI (1) | SI1869185T1 (ja) |
WO (1) | WO2006109092A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3007729T3 (da) * | 2013-06-11 | 2019-09-30 | Portage Pharmaceuticals Ltd | Struktur, fremstilling og anvendelser af humanderiverede cellegennemtrængelige peptider, der er konjugeret med specifikke biologisk aktive cargo-peptider |
MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
CN110511273B (zh) * | 2019-07-12 | 2021-06-01 | 福州市皮肤病防治院 | 一种细胞穿膜多肽的制备方法及其应用 |
CN111471095B (zh) * | 2020-01-15 | 2021-12-21 | 上海众启生物科技有限公司 | 用于阿尔茨海默症自身抗体检测的含jmjd2d蛋白片段的组合物 |
GB202019864D0 (en) | 2020-12-16 | 2021-01-27 | Anastasis Biotec Ltd | Improved cell-penetrating peptides and fusion proteins |
CN112961865B (zh) * | 2021-02-22 | 2023-06-02 | 广西大学 | 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用 |
TW202323269A (zh) * | 2021-12-08 | 2023-06-16 | 荷蘭商菲林公司 | 方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372249B1 (en) * | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
US6495526B2 (en) * | 1996-01-23 | 2002-12-17 | Gpc Biotech, Inc. | Inhibitors of cell-cycle progression and uses related thereto |
US6521602B1 (en) * | 1999-03-01 | 2003-02-18 | Gpc Biotech Inc. | Anti-neoplastic compositions and uses thereof |
GB0003284D0 (en) * | 2000-02-15 | 2000-04-05 | Secr Defence Brit | Anti-viral therapy |
IL151910A0 (en) * | 2000-04-12 | 2003-04-10 | Implyx Ltd | Compositions for drug delivery |
-
2005
- 2005-04-14 GB GB0507598A patent/GB0507598D0/en not_active Ceased
-
2006
- 2006-04-18 PT PT06726802T patent/PT1869185E/pt unknown
- 2006-04-18 CA CA 2604536 patent/CA2604536A1/en not_active Abandoned
- 2006-04-18 US US11/911,427 patent/US20080287357A1/en not_active Abandoned
- 2006-04-18 KR KR20077026274A patent/KR20080016798A/ko not_active Application Discontinuation
- 2006-04-18 EP EP20060726802 patent/EP1869185B1/en not_active Not-in-force
- 2006-04-18 ES ES06726802T patent/ES2343972T3/es active Active
- 2006-04-18 SI SI200630663T patent/SI1869185T1/sl unknown
- 2006-04-18 DK DK06726802T patent/DK1869185T3/da active
- 2006-04-18 PL PL06726802T patent/PL1869185T3/pl unknown
- 2006-04-18 AU AU2006235742A patent/AU2006235742B2/en not_active Ceased
- 2006-04-18 CN CN2006800207462A patent/CN101194017B/zh not_active Expired - Fee Related
- 2006-04-18 JP JP2008505969A patent/JP4955654B2/ja not_active Expired - Fee Related
- 2006-04-18 WO PCT/GB2006/001407 patent/WO2006109092A1/en active Search and Examination
- 2006-04-18 DE DE200660012463 patent/DE602006012463D1/de active Active
- 2006-04-18 AT AT06726802T patent/ATE458819T1/de active
-
2009
- 2009-10-29 US US12/608,718 patent/US9145446B2/en active Active
-
2015
- 2015-09-22 US US14/861,923 patent/US10259852B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2006109092A1 (en) | 2006-10-19 |
CA2604536A1 (en) | 2006-10-19 |
EP1869185A1 (en) | 2007-12-26 |
JP2008535512A (ja) | 2008-09-04 |
KR20080016798A (ko) | 2008-02-22 |
CN101194017B (zh) | 2013-08-28 |
ATE458819T1 (de) | 2010-03-15 |
CN101194017A (zh) | 2008-06-04 |
US10259852B2 (en) | 2019-04-16 |
AU2006235742B2 (en) | 2011-07-14 |
GB0507598D0 (en) | 2005-05-18 |
ES2343972T3 (es) | 2010-08-13 |
DE602006012463D1 (de) | 2010-04-08 |
US20080287357A1 (en) | 2008-11-20 |
EP1869185B1 (en) | 2010-02-24 |
US9145446B2 (en) | 2015-09-29 |
SI1869185T1 (sl) | 2010-09-30 |
AU2006235742A1 (en) | 2006-10-19 |
US20110021441A1 (en) | 2011-01-27 |
US20160068582A1 (en) | 2016-03-10 |
PT1869185E (pt) | 2010-05-28 |
PL1869185T3 (pl) | 2010-10-29 |
DK1869185T3 (da) | 2010-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10259852B2 (en) | Conjugate comprising P21 protein for the treatment of cancer | |
US10577406B2 (en) | FKBP-L polypeptides and uses in angiogenesis-mediated disorders | |
JP6030622B2 (ja) | 癌の阻害剤としてのmuc−1細胞質ドメインペプチド | |
KR101364374B1 (ko) | 생활성 fus1 펩티드 및 나노입자-폴리펩티드 복합체 | |
CN105378084B (zh) | 用于治疗癌症的方法和组合物 | |
EP1856145B1 (en) | Voltage dependent anion channel (vdac1) compositions and methods of use thereof for regulating apoptosis | |
US20160200783A1 (en) | Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation | |
JP2015533838A (ja) | rTRAIL突然変異体およびそのモノメチルアウリスタチンEコンジュゲート | |
US9314497B2 (en) | E2F as a target of hormone refractory prostate cancer | |
Kousparou et al. | Generation of a selectively cytotoxic fusion protein against p53 mutated cancers | |
CN107216371B (zh) | 一种成人t细胞白血病的特异性靶向多肽及其应用 | |
US20190030126A1 (en) | Inhibitors of the Interaction BCL-2 L10 / IP3 Receptors | |
CA3153060A1 (en) | Peptides targeting macrophages, and conjugates, compositions, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100914 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101213 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110314 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110621 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110920 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110928 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111006 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120214 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120315 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150323 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |